Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab
Status:
Active, not recruiting
Trial end date:
2023-08-19
Target enrollment:
Participant gender:
Summary
In the RESPONDER study, the role of the immune evasive mechanisms combined with genomic
characterization will be explored in urothelial cancer patients treated with second-line
treatment with pembrolizumab.
Combined profiling of immune and molecular status is novel and may contribute to improved
patient stratification and provide rationale for future treatment strategies containing
pembrolizumab.